Showing 1 - 12 results of 12 for search '"ГЕМАТОТОКСИЧНОСТЬ"', query time: 0.64s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
    Academic Journal

    Source: Medical and Clinical Chemistry; No. 3 (2018); 33-42 ; Медицинская и клиническая химия; № 3 (2018); 33-42 ; Медична та клінічна хімія; № 3 (2018); 33-42 ; 2414-9934 ; 2410-681X ; 10.11603/mcch.2410-681X.2018.v0.i3

    File Description: application/pdf

  5. 5
    Academic Journal

    Source: Medical and Clinical Chemistry; No. 1 (2018); 32-42 ; Медицинская и клиническая химия; № 1 (2018); 32-42 ; Медична та клінічна хімія; № 1 (2018); 32-42 ; 2414-9934 ; 2410-681X ; 10.11603/mcch.2410-681X.2018.v0.i1

    File Description: application/pdf

  6. 6
    Academic Journal

    Source: Russian Journal of Pediatric Hematology and Oncology; Том 7, № 1 (2020); 31-40 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 7, № 1 (2020); 31-40 ; 2413-5496 ; 2311-1267 ; 10.21682/2311-1267-2020-7-1

    File Description: application/pdf

    Relation: https://journal.nodgo.org/jour/article/view/572/533; Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev 2010;36(4):277–85. doi:10.1016/j.ctrv.2010.02.003.; Arya L., Dinand V. Current Strategies in the Treatment of Childhood Hodgkin’s Disease. Ind Ped 2005;42:1115–28. PMID: 16340052.; Hochberg J., Waxman I.M., Kelly K.M., Morris E., Cairo M.S. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol 2009;144(1):24–40. doi:10.1111/j.1365-2141.2008.07393.x.; Ekstrand B., Horning S. Hodgkin’s Disease. Blood rev 2002;16(2):111–7. doi:10.1054/blre.2002.0190.; Georgakis M.K., Karalexi M.A., Agius D., Antunes L., Bastos J., Coza D., Demetriou A., Dimitrova N., Eser S., Florea M., Ryzhov A., Sekerija M., Žagar T., Zborovskaya A., Zivkovic S., Bouka E., Kanavidis P., Dana H., Hatzipantelis E., Kourti M., Moschovi M., Polychronopoulou S., Stiakaki E., Kantzanou Μ., Pourtsidis A., Petridou E.T. Incidence and time trends of childhood lymphomas: findings from 14 Southern and Eastern European cancer registries and Surveillance, Epidemiology and End Results, USA. Cancer Causes Control 2016;27(11):1381–94. doi:10.1007/s10552-016-0817-3.; Englund A., Glimelius I., Rostgaard K., Smedby K.E., Eloranta S., Molin D., Kuusk T., Brown P.N., Kamper P., Hjalgrim H., Ljungman G., Hjalgrim L.L. Hodgkin lymphoma in children, adolescents and young adults comparative study of clinical presentation and treatment outcome. Acta Oncol 2018;57(2):276–82. doi:10.1080/0284186X.2017.1355563.; Dörffel W., Lüders H., Rühl U., Albrecht M., Marciniak H., Parwaresch R., Pötter R., Schellong G., Schwarze E.W., Wickmann L. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr 2003;215(3):139–45. PMID: 12838937.; Shankar A.G., Kirkwood A.A., Hall G.W., Hayward J., O’Hare P., Ramsay A.D. Childhood and adolescent nodular lymphocyte predominant Hodgkin lymphoma – A review of clinical outcome based on the histological variants. Br J Haematol 2015;171(2):254–62. doi:10.1111/bjh.13540.; Dieckmann K., Poetter R., Wagner W., Prott F.J., Hoernig-Franz I., Rath B., Schellong G. Up-front centralized data review and individualized treatment proposals in a multicenter pediatric Hodgkin’s disease trial with 71 participating hospitals: the experience of the German-Austrian pediatric multicenter trial DAL-HD-90. Radiother Oncol 2002;62(2):191–200. PMID: 11937246.; Mauz-Körholz C., Hasenclever D., Dörffel W., Ruschke K., Pelz T., Voigt A., Stiefel M., Winkler M., Vilser C., Dieckmann K., Karlén J., Bergsträsser E., Fossa A., Mann G., Hummel M., Klapper W., Stein H., Vordermark D., Kluge R., Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin’s lymphoma: the GPOH-HD-2002 study. J Clin Oncol 2010;28(23):3680–6. doi:10.1200/JCO.2009.26.9381.; Rühl U., Albrecht M., Dieckmann K., Lüders H., Marciniak H., Schellenberg D., Wickmann L., Dörffel W. Response-adapted radiotherapy in the treatment of pediatric Hodgkin’s disease: an interim reportat 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 2001;51(5):1209–18. doi:10.1016/s0360-3016(01)01798-9.; Zubizarreta P.A., Alfaro E., Guitter M., Sanchez La Rosa C., Galluzzo M.L., Millán N., Fiandrino F., Felice M.S. Children and Adolescent Hodgkin Lymphoma in Argentina: Long-term Results After Combined ABVD and Restricted Radiotherapy. J Pediatr Hematol Oncol 2017;39(8):602–8. doi:10.1097/MPH.0000000000000943.; Marr K.C., Connors J.M., Savage K.J., Goddard K.J., Deyell R.J. ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma. Ann Oncol 2017;28(4):849–54. doi:10.1093/annonc/mdx005.; Kelly K.M., Sposto R., Hutchinson R., Massey V., McCarten K., Perkins S., Lones M., Villaluna D., Weiner M. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children’s Oncology Group. Blood 2011;127(9):2596–603. doi:10.1182/blood-2010- 05-285379.; Charpentier A.M., Friedman D.L., Wolden S., Schwartz C., Gill B., Sykes J., Albert-Green A., Kelly K.M., Constine L.S., Hodgson D.C. Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children’s Oncology Group AHOD 0031 Trial. Int J Radiat Oncol Biol Phys 2016;96(5):943–50. doi:10.1016/j.ijrobp.2016.07.015.; Campo E., Swerdlow S., Harris N., Pileri S., Stein H., Jaffe E.S. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117(19):5019–32. doi:10.1182/blood-2011-01-293050.; Korholz D., Kluge R., Wickmann L., Hirsch W., Luders H., Lotz I. Importance of F18-fluorodeoxy-D-2-glucose positron emission tomography (FDGPET) for staging und therapy control of Hodgkin’s lymphoma in childhood and adolescence – consequences for the GPOH-HD 2003 protocol. Onkologie 2003;26(5):489–93. doi:10.1159/000072984.; Kluge R., Korholz D. Role of FDG-PET in staging and therapy of children with Hodgkin lymphoma. Klin Padiatr 2011;223(6):315–9. doi:10.1055/s-0031-1287834.; Sickinger M.T., von Tresckow B., Kobe C., Borchmann P., Engert A., Skoetz N. PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma – a systematic review and meta-analysis. Crit Rev Oncol Hematol 2016;101:86–92. doi:10.1016/j.critrevonc.2016.03.005.; Isik E.G., Kuyumcu S., Kebudi R., Sanli Y., Karakas Z., Cakir F.B., Unal S.N. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of 18 FDG-PET/CT according to ΔSUV max , Deauville 5-point scale and IHP criteria. Ann Nucl Med 2017;31(9):660–8. doi:10.1007/s12149-017-1196-x.; Gobbi P.G., Ferreri A.J., Ponzoni M., Levis A. Hodgkin lymphoma. Crit Rev Oncol Hematol 2013;85(2):216–37. doi:10.1016/j.critrevonc.2012.07.002.; Mathas S., Hartmann S., Küppers R. Hodgkin lymphoma: Pathology and Biology. Semin Hematol 2016;53(3):139–47. doi:10.1053/j.seminhematol.2016.05.007.; Sherief L.M., Elsafy U.R., Abdelkhalek E.R., Kamal N.M., Elbehedy R., Hassan T.H., Sherbiny H.S., Beshir M.R., Saleh S.H. Hodgkin lymphoma in childhood: clinicopathological features and therapy outcome at 2 centers from a developing country. Medicine (Baltimore) 2015;94(15):e670. doi:10.1097/MD.0000000000000670.; Kelly K.M. Hodgkin lymphoma in children and adolescents: improving the therapeutic index. Blood 2015;126:2452–8. doi:10.1016/j.critrevonc.2012.07.002.; Trotti A., Byhardt R., Stetz J., Gwede C., Corn B., Fu K., Gunderson L., McCormick B., Morrisintegral M., Rich T., Shipley W., Curran W. Common toxicity criteria: Version 2.0 – An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000;47(1):13–47. doi:10.1016/s0360-3016(99)00559-3.; https://journal.nodgo.org/jour/article/view/572

  7. 7
  8. 8
    Academic Journal

    File Description: application/pdf

    Relation: Усенко Т. В. Цитохімічний статус лейкоцитів периферичної крові щурів Wistar Hannover за впливу сучасних триазольних фунгіцидів / Т. В. Усенко // Вісник проблем біології і медицини. – 2018. – Вип. 2 (144). – С. 95–97.; https://repository.pdmu.edu.ua/handle/123456789/16109

  9. 9
  10. 10
  11. 11
  12. 12